Pacer Advisors’s Akebia Therapeutics AKBA Stock Holding History

Pacer Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-21,604	Closed	-$73K	–	1401
2021 Q1	$73K	Sell	21,604 -20,146	-48%	-$72.6K	﹤0.01%	1353
2020 Q4	$117K	Buy	41,750 +37,032	+785%	+$108K	﹤0.01%	1338
2020 Q3	$12K	Buy	+4,718	New	+$41.4K	﹤0.01%	1371
2018 Q4	–	Sell	-4,856	Closed	-$43K	–	548
2018 Q3	$43K	Buy	+4,856	New	+$43.4K	﹤0.01%	1150
2018 Q1	–	Sell	-900	Closed	-$13K	–	1041
2017 Q4	$13K	Buy	+900	New	+$14.9K	﹤0.01%	1127

Other funds holding AKBA

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Pacer Advisors's AKBA Position: Q2 2021 in Review

Pacer Advisors sold out of Akebia Therapeutics (AKBA) in Q2 2021, closing a stake of 21,604 shares — an estimated $73K sold.

Pacer Advisors first reported a position in AKBA in Q4 2017 and held it in 5 quarters. The position peaked at $117K in Q4 2020. 139 funds tracked by Wall St. Rank hold AKBA as of Q2 2021.

Pacer Advisors reported no remaining Akebia Therapeutics position as of Q2 2021 after selling out during the quarter.
Pacer Advisors sold 21,604 Akebia Therapeutics shares in Q2 2021, an estimated $73K.
Pacer Advisors first reported a position in Akebia Therapeutics in Q4 2017 and held it in 5 quarters.
Pacer Advisors's Akebia Therapeutics position peaked at $117K in Q4 2020.
139 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2021.

Based on Pacer Advisors's 13F filing for Q2 2021, filed 21 Jul 2021.